Finding 1080844 (2023-002)

Material Weakness Repeat Finding
Requirement
M
Questioned Costs
-
Year
2023
Accepted
2024-11-01
Audit: 326962
Organization: Rtog Foundation, Inc. (PA)

AI Summary

  • Core Issue: The Foundation lacks formal documentation and policies for monitoring subrecipient activities as required by federal regulations.
  • Impacted Requirements: Compliance with 2 CFR section 200.332, which mandates risk evaluation and monitoring of subrecipients.
  • Recommended Follow-Up: Develop and implement written policies to ensure proper monitoring of subrecipients, addressing all necessary elements of 2 CFR 200.332.

Finding Text

Finding 2023-002: Department of Health and Human Services – Research & Development Cluster – ALN #93.394, #93.395, and #93.399 – Subrecipient Monitoring Criteria: 2 CFR section 200.332 requires pass-through entities to evaluate each subrecipient’s risk of noncompliance, monitor the activities of the subrecipient as necessary to ensure that the subaward is used for authorized purposes and is in compliance with federal statutes, regulations, and the terms and conditions of the subaward, and verify that every subrecipient is audited as required by Subpart F, as necessary. Statement of Condition: No formal documentation existed to indicate that the Foundation performed the required monitoring of its subrecipient’s activity and no written policy exists to establish procedures to document the monitoring of the subrecipient. Cause: The Foundation does not have employees and is operated by a volunteer Board of Directors. Additionally, no formal policies were written to establish procedures to document monitoring of subrecipients. Effect: A failure to monitor a subrecipient's compliance with relevant federal requirements could result in noncompliance with the terms and conditions of the subawards. Subrecipient monitoring was ineffective. Questioned Costs: None. Identification as a Repeat Finding: Not a repeat finding. Recommendation: We recommend that the Foundation establish written policies to document the monitoring of its subrecipient by an individual independent of the subrecipient. This policy should address all required elements of 2 CFR 200.332. Views of Responsible Officials: Management agrees with finding; see separate corrective action plan.

Categories

Subrecipient Monitoring

Other Findings in this Audit

  • 504393 2023-001
    Significant Deficiency Repeat
  • 504394 2023-002
    Material Weakness Repeat
  • 504395 2023-001
    Significant Deficiency Repeat
  • 504396 2023-002
    Material Weakness Repeat
  • 504397 2023-001
    Significant Deficiency Repeat
  • 504398 2023-002
    Material Weakness Repeat
  • 504399 2023-001
    Significant Deficiency Repeat
  • 504400 2023-002
    Material Weakness Repeat
  • 504401 2023-001
    Significant Deficiency Repeat
  • 504402 2023-002
    Material Weakness Repeat
  • 504403 2023-001
    Significant Deficiency Repeat
  • 504404 2023-002
    Material Weakness Repeat
  • 1080835 2023-001
    Significant Deficiency Repeat
  • 1080836 2023-002
    Material Weakness Repeat
  • 1080837 2023-001
    Significant Deficiency Repeat
  • 1080838 2023-002
    Material Weakness Repeat
  • 1080839 2023-001
    Significant Deficiency Repeat
  • 1080840 2023-002
    Material Weakness Repeat
  • 1080841 2023-001
    Significant Deficiency Repeat
  • 1080842 2023-002
    Material Weakness Repeat
  • 1080843 2023-001
    Significant Deficiency Repeat
  • 1080845 2023-001
    Significant Deficiency Repeat
  • 1080846 2023-002
    Material Weakness Repeat

Programs in Audit

ALN Program Name Expenditures
93.395 Cancer Treatment Research $2.20M
93.399 Cancer Control $664,945
93.394 Cancer Detection and Diagnosis Research $12,018